Irbesartan/Hydrochlorothiazid Aurobindo

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartan/Hydrochlorothiazid Aurobindo, is an angiotensin II receptor blocker/thiazide diuretic presented as an oral tablet for systemic use. It is prescribed to lower elevated blood pressure in adults and helps reduce the risk of cardiovascular complications associated with hypertension.

GNH USA supplies Irbesartan/Hydrochlorothiazid Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is used in the management of hypertension, a condition characterized by persistently high arterial pressure.

- Essential hypertension: lowers systolic and diastolic blood pressure to target levels. - Secondary hypertension: assists in controlling blood pressure when caused by other underlying disorders. - Hypertensive patients with fluid retention: provides additional diuretic effect to reduce volume overload.

The combination may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia or hyponatremia - Angioedema - Liver function abnormalities - Blood dyscrasias (e.g., agranulocytosis)

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor relevant parameters.

- Renal function: assess creatinine clearance and adjust if impaired. - Electrolytes: monitor potassium and sodium levels regularly. - Cardiovascular status: watch for symptomatic hypotension, especially after the first dose. - Concomitant drugs: review for potential interactions that affect blood pressure or renal handling. - Pregnancy and lactation: avoid use unless clearly indicated and benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may alter the pharmacokinetic or pharmacodynamic profile of several co‑administered medicines.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of additive renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: increased lithium levels leading to toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive efficacy and impair renal function. - Antidiabetic agents: diuretic‑induced electrolyte changes can affect glucose control. - CYP2C9 substrates (e.g., warfarin): irbesartan may alter metabolism, requiring INR monitoring.